|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The important role of skin biopsies in the diagnosis of mpox显示文摘Human monkeypox(mpox)is an emerging zoonosis endemic in several Central and West African countries[1].There are two known clades of mpox virus—one that originated in Central Africa(Clade I)and one that originated in West Africa(Clade II).However,cases of mpox have been reported from countries where the disease is not endemic,especially during the 2003 outbreak in the U.S.[2]and the 2022 global outbreak[3,4].The mpox virus in the 2003 U.S.outbreak was transmitted from imported African rodents to domestic North American prairie dogs and subsequently to humans in contact with infected animals[5].No evidence of human‐to‐human transmission was identified,and most of the human cases presented with scattered skin lesions.The transmission route of the 2022 global outbreak,on the contrary,was mainly through intimate human‐to‐human contact,and many cases showed abundant skin lesions with mucosal involvement[6–8]. | Wun-Ju Shieh | 2023 | iLABMED2023，1，3： | 0 |
| 2 | Overview of the epidemic characteristics of Mycoplasma pneumoniae infection around COVID pandemic显示文摘Mycoplasma pneumoniae(M.pneumoniae)is a cell wall‐less respiratory pathogen causing community‐acquired pneumonia and extrapulmonary manifestations.It is transmitted through close contact and shows periodic regional outbreaks.The coronavirus disease(COVID‐19)pandemic interfered with the global spread of M.pneumoniae.A large‐scale post‐COVID outbreak is currently ongoing in China.To help physicians better understand and manage this epidemic,we provide this review summarizing current knowl-edge on the pathogenesis,epidemic characteristics,macrolide resistance,diagnostic methods,and clinical treatment strategies for this pathogen. | Hongmei Sun Li Xiao | 2023 | iLABMED2023，1，3： | 0 |
| 3 | Significant histological changes are not rare in indeterminate‐phase chronic hepatitis B patients with hepatitis B e antigen‐negative and normal alanine aminotransferase levels显示文摘Background&Objectives:The degree of liver injury in indeterminate chronic hepatitis B(CHB)infection patients with Hepatitis B e antigen(HBeAg)‐negative and persistently normal alanine aminotransferase(PNALT)levels is yet unclear.Therefore,we aimed to assess liver histological changes in such patients by liver biopsy and explore possible predictors.Methods:Overall,711 HBeAg‐negative CHB patients with PNALT levels who underwent liver biopsy from January 2017 to June 2022 were included in this retrospective study.The relationships between histological changes and predictors were assessed by smooth curve fitting and multivariate logistic regression analysis models.Data were also analyzed using American Association for the Study of Liver Disease(AASLD)modified alanine aminotransferase(ALT)criteria.Results:The proportion of significant histological changes in the indeterminate phase was higher than that in the inactive phase(53.97%vs.41.33%).The adjusted odds ratios(aORs)of significant necroinflammation and histological changes for the indeterminate phase were 2.05 and 1.43,respectively,when compared with the inactive phase by multivariate logistic regression analyses.Significant histological changes in the‐phase were positively associated with age,ALT,Aspartate aminotransferase(AST),Hepatitis B surface antigen(HBsAg),and Hepatitis B virus(HBV)DNA levels but negatively correlated with platelet(PLT)levels.HBV DNA≥5 log10 U/L and PLT<200�109/L were independent predictive factors for assessing histological changes in indeterminate‐phase patients.Similar analysis findings were obtained using the two sets of modified ALT criteria.Conclusions:Significant histological changes are not rare in indeterminatephase CHB patients and are higher than in the inactive phase,regardless of the ALT criteria.Histological investigation is strongly suggested for intermediate stage patients with HBV DNA>5 log10 U/L or PLT<200�109/L and antiviral therapy should be considered for such patients. | Deliang Huang Guangde Zhou Jinghan Peng Qinxian Cai Guojun Li Hong Yu Zhibing Zhu Yuanyuan Chen Huiyi Lai Jinyan Jiang Hong Yu Jun Chen | 2023 | iLABMED2023，1，3： | 0 |
| 4 | Investigating Torsin‐1A‐interacting protein 1 as a predictive and immunological biomarker in cancer显示文摘Background:Cancer poses a significant global challenge,and with the pro-jected rise in cancer incidence,there is an urgent need to discover new targets and treatments to improve patient outcomes.Recent advancements in geno-mics technologies have enhanced our understanding of cancer's complexities and led to the emergence of pan‐cancer analysis as a valuable approach for identifying tumor targets.Torsin‐1A‐interacting protein 1(TOR1AIP1)is a membrane protein involved in various cellular processes.Emerging evidence suggests its potential involvement in cancer.Methods:In this study,we conducted a comprehensive analysis of multiple databases to explore TOR1AIP1 expression across different cancer types and stages.We also investigated its correlation with clinical outcomes,such as survival rates and drug sensitivity.Results:The results of our analysis showed significant deregulation of TOR1AIP1 expression in multiple cancer types and its association with clinical outcomes,with a particular emphasis on kidney renal clear cell carcinoma.The results of our study highlight the potential predictive value of TOR1AIP1 in cancer prognosis and therapy.Conclusions:This study establishes a solid foundation and rationale for future experimental investigations,which will contribute to a deeper under-standing of the significance of TOR1AIP1 in different cancer types,specifically in kidney renal clear cell carcinoma. | Gurleen Kaur Gurparsad Singh Suri Dheeraj Shinde | 2023 | iLABMED2023，1，3： | 0 |
| 5 | Clinical validation of serum immunosignatures in early diagnosis of Crohn's disease显示文摘Background:The search for biomarkers suitable for early diagnosis of Crohn's disease(CD)is challenging.This study investigated the efficacy of serological markers for the early diagnosis of CD.Methods:This was a retrospective nested cohort study.Indirect immuno-fluorescence and enzyme‐linked immunosorbent assay were used to detect ASCA IgG,ASCA IgA,AYMA IgG,AYCA IgG,FI2Y IgG,p‐ANCA IgG,GAB IgG and PAB IgG in patient serum samples.Results:The positive rates of ASCA IgG,ASCA IgA,AYMA IgG,AYCA IgG,FI2Y IgG,p‐ANCA IgG,GAB IgG and PAB IgG in patients with early CD,advanced CD and other intestinal diseases were 37.0%versus 56.8%versus 27.8%;3.7%versus 20.5%versus 19.4%;14.8%versus 2.3%versus 2.8%;25.9%versus 9.1%versus 8.3%;18.5%versus 15.9%versus 8.3%;0.0%versus 2.8%,18.5%;13.6%versus 18.2%versus 16.7%;and 7.4%versus 20.5%versus 0.0%,respectively.The positive rates of ASCA IgG,AYCA IgG and PAB IgG were significantly different among the three groups(p<0.05).In 85.2%of early CD patients,at least one antibody was detected 1 year before diagnosis.The sensitivity of the ASCA/AYMA/AYCA/FI2Y/GAB combination for early diagnosis was 85.2%.The sensitivity of the ASCA/AYMA/AYCA/FI2Y/GAB/PAB/PANCA combination for differentiating CD from other diseases was 87.3%.Conclusions:ASCA IgG and AYCA IgG have potential value in identifying the course of CD.AYCA IgG may be a potential marker for the early diagnosis of CD,and ASCA IgG indicates an advanced stage.The combination of ASCA,AYMA,AYCA,FI2Y,and GAB improves early diagnostic accuracy of CD. | Xianzong Ma Wenyu Zhang Xin Wang Lang Yang Juan Jiao Yan Jia Dezhi Wang Junfeng Xu Peng Jin Mingjie Zhang Shirong Li Yuanming Pan Jianqiu Sheng | 2023 | iLABMED2023，1，3： | 0 |
| 6 | Mutating Escherichia coli caused multiple organ dysfunction syndrome显示文摘Pathogenic Escherichia coli is of great concern in the clinical setting.But few reports have demonstrated the variation in disease course.We present a severe case of multiple organ dysfunction syndrome caused by E.coli infection.Pathogens isolated from blood and urine samples harboured many virulence factors.Whole‐genome sequencing and conventional analyses showed that the isolates experienced beneficial variations,both genetically and phenotypically,during the disease course.These findings showed that E.coli can cause sys-temic symptoms and informed us of the importance of assessing the reasons for such variations in pathogens occurring in vivo. | Lihua Qi Wencheng Xue Xuelin Liu Shaofu Qiu Jie Liu | 2023 | iLABMED2023，1，3： | 0 |
| 7 | The incidence of liver abnormalities is higher in inactive hepatitis B virus carriers with influenza A infection显示文摘1INTRODUCTION China is still at a high risk of hepatitis B virus(HBV)infection and has a large number of inactive HBV carriers(ICs)[1].Chronic hepatitis B viral infection is a global problem,which commonly progresses to liver cirrhosis[2],hepatocellular carcinoma[3],and liver diseaserelated death[4]. | Liqin Sun Yong-Mei Yin Nan Xiao Cheng Wang Xiao-Guang Li Jun Wang Hongzhou Lu | 2023 | iLABMED2023，1，2： | 0 |
| 8 | Focus on lipoprotein(a):The time is now显示文摘1INTRODUCTION Low-density lipoprotein cholesterol(LDL-C)is the most important risk factor for atherosclerotic cardiovascular disease(ASCVD),but some individuals who meet the LDL-C treatment goal still have a residual risk of ASCVD[1].Numerous clinical studies and meta-analyses have shown that high lipoprotein(a)(Lp(a))concentration is a continuous,independent,and moderately significant risk factor for ASCVD,and that this association is not dependent on LDL-C or non-HDL-C levels or other risk factors[2]. | Ya-hui Lin Qiong Yang Zhou Zhou | 2023 | iLABMED2023，1，2： | 0 |
| 9 | Application of autoantibody detection in chronic liver disease显示文摘Autoantibody(AAb)detection has become one of the standards of diagnosis for autoimmune liver disease(AILD),and some AAbs have become specific biomarkers of AILD.In addition,AAbs can be detected in patients with non-AILDs,such as viral hepatitis and alcoholic liver disease.However,the distribution characteristics and pathogenic mechanisms of AAbs in patients with non-AILD are unclear.This article summarizes the characteristics of AAbs in several common clinical chronic liver diseases(CLDs)and discusses the value of AAb analysis in CLD. | Jinyu Han Jin Chen Yajie Wang | 2023 | iLABMED2023，1，2： | 0 |
| 10 | The mechanism of copper homeostasis and its role in disease显示文摘Copper(Cuprum)is an essential trace metal indispensable for the function of numerous enzymatic molecules implicated in cellular metabolism.Emerging evidence has demonstrated the role of copper in angiogenesis and cellular signaling.Moreover,raised copper levels have been detected in hepatocellular carcinoma and other cancers.An inherited or acquired copper imbalance,including inadequately low or excessively high copper levels,as well as inappropriate copper distribution in the body,is implicated in a number of diseases.In addition,a recent groundbreaking study identified a copperinduced type of programmed cell death named cuprotosis,the mechanism of which greatly deferred from that of other known cell death modes.The first part provides an overview of the regulation of copper homeostasis and discusses the underlying mechanisms of cuprotosis.In the second part,the authors focus on the functions of copper in liver diseases and other metabolic disorders,before discussing how this knowledge could contribute to the development of effective targets to treat such diseases. | Yunhui Li Jing Liang Yuan Chen Yajie Wang | 2023 | iLABMED2023，1，2： | 0 |
| 11 | An iASPP-derived short peptide restores p53-mediated cell death in cancers with wild-type p53显示文摘Background:Inhibitor of apoptosis-stimulating protein of p53(iASPP)is an evolutionarily conserved p53 inhibitor.Mechanistically,iASPP can accelerate tumorigenesis by inhibiting the transactivation function of p53.Targeting the interaction between iASPP and p53 may be a potential therapy for restoring the activity of p53 in tumors.Methods:We constructed an iASPP-derived peptide,called A8,that was derived from the C-terminus of iASPP.Here,we transfected A8 into two wildtype(WT)p53 cell lines,U2OS and A549,and then determined the number of apoptotic cells.The mechanism by which A8 affected apoptosis was further examined by immunoprecipitation(IP),Dual-Luciferase reporter assays,and chromatin IP assays.Real-time polymerase chain reaction and western blots were also used to examine the expression levels of apoptosis-related factors.Results:Our data demonstrate that A8 can increase apoptosis rates in WT p53 cell lines.Functional analysis suggested that A8 restored the transcriptional function and DNA binding activities of p53 toward the Bax and PUMA gene promoters.Moreover,A8 reduced cell proliferation and inhibited tumor growth in xenograft nude mice.Conclusions:These data provide a new approach for restoring the tumor suppressor function of p53 in cancer cells that express WT p53 and therefore may serve as a novel cancer treatment strategy. | Shi Qiu Wei Qi Wen Wu Qian Qiu Jiali Ma Yingjun Li Wenhui Fan Junli Li Yang Xu Hai Chen Jie Liu | 2023 | iLABMED2023，1，2： | 0 |
| 12 | Clinical utility of six serum tumor markers for the diagnosis of lung cancer显示文摘Background:With the increasing prevalence of lung cancer,it has become imperative to identify reliable biomarkers that can aid in early detection and prognosis assessment.Therefore,we sought to investigate the potential utility of six serum tumor markers as diagnostic and prognostic tools for lung cancer patients.By analyzing a large cohort of patients with different stages and subtypes of lung cancer,we hoped to shed light on the predictive value and accuracy of each marker individually,as well as their combined performance.This study should not only provide valuable insights into the biology and pathogenesis of lung cancer but also pave the way for personalized treatment strategies based on individual patient profiles.Methods:The serum levels of the tumor markers progastrin-releasing peptide(ProGRP),carcinoembryonic antigen(CEA),neuron-specific enolase(NSE),cytokeratin 19 fragment(CYFRA21-1),carbohydrate antigen 19-9(CA19-9)and squamous cell carcinoma antigen(SCCA)were meticulously assessed in a cohort comprising 324 individuals diagnosed with lung cancer and an additional 51 patients with benign lung disease.The measurements were conducted using cutting-edge techniques such as ELISA,electrochemical luminescence,and chemiluminescence methods.Differences between groups and the impact of these markers on lung cancer diagnosis were analyzed.Results:The serum levels of ProGRP,NSE,and CEA were significantly higher in lung cancer patients than in patients with benign lung disease(p<0.01).NSE had the highest sensitivity for squamous cell carcinomas(SC),while CEA had the highest sensitivity for adenocarcinomas(AC).ProGRP and NSE had higher sensitivities than other markers for small cell carcinomas(SCC).Combining the six tumor markers resulted in higher sensitivities for SC(70.6%),AC(77.4%),and SCC(80%)compared with any single test.Receiver operator characteristic analysis showed that ProGRP and NSE had a greater area under the curve(AUC)in SCC(0.886 and 0.775)than SC and AC,while CEA had a higher AUC in AC(0.716),and NSE had a higher AUC than other markers in SC(0.719).Conclusions:ProGRP and NSE are effective serum tumor markers for SCC,whereas CEA and NSE may aid in the diagnosis of AC and SC.Combining the detection of ProGRP,NSE,CYFRA21-1,CEA,and SCCA significantly improves sensitivity when diagnosing lung cancer. | Yongchang Yang Shuai Chang Na Wang Pengfei Song Haijing Wei Jie Liu | 2023 | iLABMED2023，1，2： | 0 |
| 13 | iLABMED,why now and how in the future?显示文摘Nowadays,public health is facing many challenges,mainly including non‐communicable diseases and communicable diseases.Communicable diseases,particularly emerging infectious diseases,have also attracted attention due to their enormous impact on public health and the global economy.The most prominent example is the current global Coronavirus Disease 2019(COVID‐19)pandemic.The unprece-dented and ongoing COVID‐19 pandemic has high-lighted the necessity for readily available,accurate,and rapid laboratory medicine(LM)practices.Nevertheless,current LMs and journals in particular have a window for improvement.First,there are limited numbers of professionals available in this field compared to the other disciplines.The current status quo is that most LM manuscripts must be submitted to comprehensive journals or other journals related to the research disease.Second,most LM journals are run by laboratory personnel who are often more concerned with technical advances than with clinical needs.Lastly,several young LM scientists expressed their desire to have a dedicated platform to discuss,communicate,and publish their works on LM.We were therefore motivated to launch iLABMED,an international public forum dedicated to LMs.The establishment of iLABMED adopts the“four I”strat-egy,namely“Innovation,”“Intelligence,”“Integra-tion,”and“International.”We are attempting to establish a top‐tier journal in the field of LM. | Hongzhou Lu | 2023 | iLABMED2023，1，1： | 0 |
| 14 | Single cell metabolic phenome and genome via the ramanome technology platform:Precision medicine of infectious diseases at the ultimate precision?显示文摘Due to the limitations of existing approaches,a rapid,sensitive,accurate,comprehensive,and generally applicable strategy to diagnose and treat bacterial and fungal infections remains a major challenge.Here,based on the ramanome technology platform,we propose a culture‐free,one cell resolution,phenome‐genome‐combined strategy called single‐cell identification,viability and vitality tests and source tracking(SCIVVS).For each cell directly extracted from a clinical specimen,the fingerprint region of the D2O‐probed single cell Raman spectrum(SCRS)enables species‐level identification based on a reference SCRS database of pathogen species,whereas the C‐D band accurately quantifies viability,metabolic vitality,phenotypic susceptibility to antimicrobials,and their intercellular heterogeneity.Moreover,to source track a cell,Raman‐activated cell sorting followed by sequencing or cultivation proceeds,producinging an indexed,high coverage genome assembly or a pure culture from precisely one pathogenic cell.Finally,an integrated SCIVVS workflow that features automated profiling and sorting of metabolic and morphological phenomes can complete the entire process in only a few hours.Because it resolves heterogeneity for both the metabolic phenome and genome,targets functions,can be automated,and is orders‐of‐magnitude faster while cost‐effective,SCIVVS is a new technological and data framework to diagnose and treat bacterial and fungal infections in various clinical and disease control settings. | Jian Xu Jianzhong Zhang Yingchun Xu Yi‐Wei Tang Bo Ma Yuzhang Wu | 2023 | iLABMED2023，1，1： | 0 |
| 15 | Interim proposal for collecting and handling of microbiology specimens from patients with COVID‐19 in general hospitals显示文摘1|INTRODUCTION Accurate pathogenic testing is essential for early diag-nosis and precise treatment of COVID‐19,and correct specimen collection and handling is vital for accurate diagnosis[1].With the continuing mutations,the pathogenicity of Severe acute respiratory syndrome coronavirus 2(SARS‐CoV‐2)has gradually decreased,so the management of COVID‐19 in China has been down-graded to Class B(http://gffzz70f342d5f30647b7h0p06kpbk069p6fx6.ffgz.tsg.suse.edu.cn).Infections with different SARS‐CoV‐2 variants produce variable clinical manifestations,and the types of specimens vary accordingly[2].The purpose of developing this guideline was to standardize the process of specimen collection and handling for microbiological testing from patients with confirmed or suspected COVID‐19 to avoid incorrect diagnosis and treatment. | Zhaofang Jiang Shan Chen Jiayao Qu Siyuan Liu Tao Hong Houming Liu Yi‐Wei Tang Jiuxin Qu Hongzhou Lu | 2023 | iLABMED2023，1，1： | 0 |
| 16 | Comparison of an automated digital cell morphology analysis system with manual counting显示文摘Background:Bionovation's CSFA800 is a new automated digital cell imaging analyzer.We evaluated the performance of the CSFA800 by comparing it with artificial peripheral blood white blood cell counting.Methods:According to inclusion and exclusion criteria,131 randomly selected samples(77 abnormal samples and 54 normal samples)were compared.Correlations between automated and manual counting results were analyzed.Manual counting was carried out according to the guidelines of the Association of Clinical and Laboratory Standards.Results:Counts of neutrophils,lymphocytes,monocytes,eosinophils,baso-phils,and immature granulocytes obtained from CSFA800 and artificial methods were linearly and positively correlated,with R values of 0.73,0.65,0.24,0.2,0.4,and 0.63,respectively,all p<0.05.Therefore,correlations be-tween CSFA800 and manual counting are acceptable.Compared with the DI‐60 Automated Digital Cell Morphology System(DI‐60;Sysmex),CSFA800 is more efficient and can analyze 20,000 cells in 1 min.However,the overall accuracy of CSFA800 is not as good as DI‐60,although its counting perfor-mance is better for basophils.Conclusions:The performance of CSFA800 for WBC counts is acceptable,and it displayed good performance for neutrophils,lymphocytes,and imma-ture granulocytes.Compared to DI‐60,CSFA800 is more efficient but has slightly lower overall accuracy.To some extent,CSFA800 is helpful to opti-mize the clinical laboratory workflow and improve the working efficiency of inspectors. | Juan Jiao Xin Yin Jiali Ma Yinglong Xia Jianxia Xu Shaozhe Zhao Jie Liu | 2023 | iLABMED2023，1，1： | 0 |
| 17 | Target selection and clinical chimeric antigen receptor T cell activity against solid tumors显示文摘Chimeric antigen receptor(CAR)T cell therapy is a relatively new form of targeted therapy that has demonstrated impressive success in treating hematological malignancies.It has been challenging to translate this success to solid tumors.Reasons for this include barriers to delivery,tumor heterogeneity,cancer cells'ability to evade the immune system as well as identifying the optimal target.Most CAR T clinical trials have targeted well‐characterized cancer targets with significant preclinical and in some cases clinical validation.Published results from some of these trials show signs of anti‐cancer activity that warrant encouragement,but also caution,given instances of unacceptable toxicity.The narrow therapeutic window is complicated by the ability of CAR T cells to expand in patients regardless of dose.Here,we review those trials showing encouraging results in the context of target selection.It is clear that more specific tumor targeting is required,either by affinity tuning to avoid low‐level target expression in healthy cells,logic gating,or the identification of new targets that are more cancer specific. | Eric von Hofe Yanping Yang Moonsoo M.Jin | 2023 | iLABMED2023，1，1： | 0 |
| 18 | Bottlenecks and recent advancements in detecting Mycobacterium tuberculosis in patients with HIV显示文摘Tuberculosis(TB)remains a leading cause of deaths among patients with acquired immunodeficiency syndrome patients.Early diagnosis of TB is essential for administering timely anti‐TB therapy and improving health out-comes,particularly in the people living with HIV.However,conventional techniques used to detect Mycobacterium tuberculosis have significant draw-backs:for example,sputum smear microscopy has low sensitivity,and liquid culture is time‐consuming in patients with HIV‐TB co‐infection due to low sputum production.In addition,while immunological‐based methods involving tuberculin skin testing and interferon gamma release assays are commonly used for auxiliary TB diagnosis,they are often inaccurate in immunodeficient patients.Molecular techniques such as line probe assays,Xpert MTB,and lipoarabinomannan assay are recommended for early diagnosis by World Health Organization.However,no single technique is sufficicent for diagnosing HIV/TB co‐infection,suggesting that multiple diagnostic tests should be used to detect TB.Here,we summarize the drawbacks and advantages of existing TB‐diagnostic methods,as well as their applications to diagnosing HIV/TB co‐infection.We describe newly emerging technologies such as whole genome sequencing and mass spectrometry,with the aim of providing updated guidelines and alternative strategies for TB diagnosis,and particularly HIV/TB diagnosis. | Zixun Lin Liqin Sun Cheng Wang Fuxiang Wang Jun Wang Qian Li Hongzhou Lu | 2023 | iLABMED2023，1，1： | 0 |
| 19 | Research progress of CRISPR/Cas systems in nucleic acid detection of infectious diseases显示文摘Infectious diseases are a serious threat to human health,and accurate,rapid and convenient early detection of pathogens is the first step of active treatment.Technologies that detect pathogens have advanced significantly because of the development of fundamental disciplines and the integration of multidisciplinary fields.Among these technologies,nucleic acid detection technology is preferred because of its rapid measurement,accuracy and high sensitivity.The CRISPR/Cas system,consisting of Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR)and CRISPR‐associated(Cas),is an adaptive immune system that specifically recognizes,binds and cleaves exogenous invasive nucleic acids.The CRISPR/Cas system is widely found in bacteria and archaea.Researchers have developed nucleic acid detection technologies with single‐molecule sensitivity,single‐base precision specificity,portability and low cost based on the specific cleavage and trans‐cleavage activities of the CRISPR/Cas system.The next generation of in‐vitro diagnostics is shifting to nucleic acid technology because this technology shows promise in a wide range of applications in resource‐constrained environments.In this review,the development and mechanism of the CRISPR/Cas system are presented together with representative CRISPR/Cas applications in nucleic acid detection.Additionally,the review summarizes future perspectives and trends of the CRISPR/Cas system in nucleic acid detection. | Jinying Dong Yuguang Du Lei Zhou | 2023 | iLABMED2023，1，1： | 0 |
| 20 | Quality management in anatomic pathology:The past,present,and future显示文摘One of the challenges in anatomic pathology laboratories is to meet the increasing need for pathological diagnosis,using quality management(QM)activities and systems to ensure that patients receive their accurate and timely pathology report.The aim of this paper is to review anatomic pa-thology QM from both management and technical perspectives,including the past,present,and future opportunities.First,the evolution of the QM concept and scope will be discussed.Next,current QM system imple-mentation and laboratory accreditations will be discussed from the man-agement perspective,and common medical errors in anatomic pathology in different testing cycles will be analyzed.Finally,selected future management systems to improve the level of total QM worldwide for patient safety and the potential of informatics to be used as an auxiliary tool in anatomic pathology will be discussed. | Chenguang Xi Dengfeng Cao | 2023 | iLABMED2023，1，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员